Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation
ABSTRACTBackground: The V617F mutation of Janus-associated kinase 2 (JAK2) is common in myeloproliferative neoplasms (MPN). JAK2 V617F mutation can be detected in patients with de novo acute myeloid leukemia (AML), but de novo acute promyelocytic leukemia (APL) with JAK2 V617F mutation is rare.Case...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2022.2153200 |
| _version_ | 1811309718452305920 |
|---|---|
| author | Yi-zhi Jiang Zhong-ling Wei Na-na Wang Chen Huang Jun Huang Jia-wei Yan Ran Wang Zheng-zhi Yu Dong-ping Huang |
| author_facet | Yi-zhi Jiang Zhong-ling Wei Na-na Wang Chen Huang Jun Huang Jia-wei Yan Ran Wang Zheng-zhi Yu Dong-ping Huang |
| author_sort | Yi-zhi Jiang |
| collection | DOAJ |
| description | ABSTRACTBackground: The V617F mutation of Janus-associated kinase 2 (JAK2) is common in myeloproliferative neoplasms (MPN). JAK2 V617F mutation can be detected in patients with de novo acute myeloid leukemia (AML), but de novo acute promyelocytic leukemia (APL) with JAK2 V617F mutation is rare.Case presentation: We report a case of APL with both the t(15;17) translocation as well as the JAK2 V617F mutation that transformed into MPN (PV/ET).Conclusions: A de novo APL patient presented initially with JAK2 V617F. After ATRA and ATO dual induction and chemotherapy consolidation, the patient achieved complete remission (CR) with undetectable PML/RARα. However, the JAK2 V617F remained positive, and the patient developed MPN (PV/ET) 22 months later, which responded well to interferon therapy.AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; ATO, arsenic trioxide; BM, bone marrow; CR, complete remission; ET, essential thrombocythemia; Hb, hemoglobin; JAK2, Janus-associated kinase 2; MPN, myeloproliferative neoplasms; PLT, platelets; PMF, primary myelofibrosis; PML/RARα; PV, polycythemia vera; WBC, white blood cells. |
| first_indexed | 2024-04-13T09:46:20Z |
| format | Article |
| id | doaj.art-12506528c7a7407c9814715c7a58a296 |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-04-13T09:46:20Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-12506528c7a7407c9814715c7a58a2962022-12-22T02:51:44ZengTaylor & Francis GroupHematology1607-84542022-12-012711290129310.1080/16078454.2022.2153200Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutationYi-zhi Jiang0Zhong-ling Wei1Na-na Wang2Chen Huang3Jun Huang4Jia-wei Yan5Ran Wang6Zheng-zhi Yu7Dong-ping Huang8Department of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, People’s Republic of ChinaABSTRACTBackground: The V617F mutation of Janus-associated kinase 2 (JAK2) is common in myeloproliferative neoplasms (MPN). JAK2 V617F mutation can be detected in patients with de novo acute myeloid leukemia (AML), but de novo acute promyelocytic leukemia (APL) with JAK2 V617F mutation is rare.Case presentation: We report a case of APL with both the t(15;17) translocation as well as the JAK2 V617F mutation that transformed into MPN (PV/ET).Conclusions: A de novo APL patient presented initially with JAK2 V617F. After ATRA and ATO dual induction and chemotherapy consolidation, the patient achieved complete remission (CR) with undetectable PML/RARα. However, the JAK2 V617F remained positive, and the patient developed MPN (PV/ET) 22 months later, which responded well to interferon therapy.AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; ATO, arsenic trioxide; BM, bone marrow; CR, complete remission; ET, essential thrombocythemia; Hb, hemoglobin; JAK2, Janus-associated kinase 2; MPN, myeloproliferative neoplasms; PLT, platelets; PMF, primary myelofibrosis; PML/RARα; PV, polycythemia vera; WBC, white blood cells.https://www.tandfonline.com/doi/10.1080/16078454.2022.2153200Acute promyelocytic leukemia (APL)myeloproliferative neoplasms (MPN)JAK2 v617fPML/RARαtransformation |
| spellingShingle | Yi-zhi Jiang Zhong-ling Wei Na-na Wang Chen Huang Jun Huang Jia-wei Yan Ran Wang Zheng-zhi Yu Dong-ping Huang Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation Hematology Acute promyelocytic leukemia (APL) myeloproliferative neoplasms (MPN) JAK2 v617f PML/RARα transformation |
| title | Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation |
| title_full | Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation |
| title_fullStr | Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation |
| title_full_unstemmed | Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation |
| title_short | Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation |
| title_sort | clinical characteristics of a patient with de novo acute promyelocytic leukemia with jak2 v617f mutation |
| topic | Acute promyelocytic leukemia (APL) myeloproliferative neoplasms (MPN) JAK2 v617f PML/RARα transformation |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2022.2153200 |
| work_keys_str_mv | AT yizhijiang clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation AT zhonglingwei clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation AT nanawang clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation AT chenhuang clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation AT junhuang clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation AT jiaweiyan clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation AT ranwang clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation AT zhengzhiyu clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation AT dongpinghuang clinicalcharacteristicsofapatientwithdenovoacutepromyelocyticleukemiawithjak2v617fmutation |